BIO-Europe® 2016: Atlantic Healthcare outlines filing plans

December 6, 2016
Toby Wilson Waterworth, CEO of Atlantic Healthcare, speaks to Mike Ward, global director of content for Informa Pharma Intelligence, about the company's recent fundraising and next stages of development for the business. Wilson Waterworth also outlines Atlantic's development and filing plans for lead product, alicaforsen, for the treatment of pouchitis—a condition for which there are currently no approved treatments. Atlantic has an exclusive licensing agreement with Ionis Pharmaceuticals Inc. (formerly ISIS Pharmaceuticals) for the global rights to alicaforsen, for which it has several preclinical and clinical programs ongoing in ulcerative colitis and other gastrointestinal disorders. As a point of clarification, Atlantic Healthcare has the basis of an agreement with the FDA to start a Phase III trial in ulcerative colitis (4min20).
Previous Video
BIO-Europe® 2016: InflaRX CEO highlights pipeline goals
BIO-Europe® 2016: InflaRX CEO highlights pipeline goals

Neils Riedemann, founder and CEO of InflaRX, speaks to Lucie Ellis, senior writer at Scrip, about the compa...

Next Video
BIO-Europe® 2016: Vaximm seeks pharma partners for T-cell/checkpoint inhibitor combos
BIO-Europe® 2016: Vaximm seeks pharma partners for T-cell/checkpoint inhibitor combos

Dr. Matthias Schroff, the new CEO of privately-held Swiss vaccines company Vaximm, talks to Mike Ward, glob...